Kairos Pharma engages Barretto Pacific Corporation for investor relations services.
PorAinvest
jueves, 12 de junio de 2025, 5:09 pm ET1 min de lectura
KAPA--
Kairos Pharma has recently announced that it has entered into an agreement with Barretto Pacific Corporation to provide services related to disseminating public information about the company's business and affairs in the US to investment professionals and private parties. The services will commence on June 10, 2025, and will be in consideration of the company's payment of the agreed fee.
This move by Kairos Pharma aims to enhance transparency and communication with stakeholders, a critical aspect for any publicly traded company. The engagement with Barretto Pacific, a well-known firm in the industry, suggests that Kairos Pharma is committed to maintaining high standards of corporate governance and investor relations.
The agreement is effective from June 10, 2025, and the services will be provided in line with the company's payment schedule. This strategic partnership underscores Kairos Pharma's dedication to ensuring that its operations and financial health are communicated effectively to a wide range of audiences.
References
[1] https://www.benzinga.com/analyst-stock-ratings/analyst/591c741c290fa70001b157cb/jason-kolbert
Kairos Pharma has engaged Barretto Pacific Corporation to provide services including disseminating public information about the company's business and affairs in the US to investment professionals and private parties. The services will be in consideration of the company's payment of the agreed fee. The agreement is effective from June 10, 2025.
Title: Kairos Pharma Engages Barretto Pacific for US Public Information DisseminationKairos Pharma has recently announced that it has entered into an agreement with Barretto Pacific Corporation to provide services related to disseminating public information about the company's business and affairs in the US to investment professionals and private parties. The services will commence on June 10, 2025, and will be in consideration of the company's payment of the agreed fee.
This move by Kairos Pharma aims to enhance transparency and communication with stakeholders, a critical aspect for any publicly traded company. The engagement with Barretto Pacific, a well-known firm in the industry, suggests that Kairos Pharma is committed to maintaining high standards of corporate governance and investor relations.
The agreement is effective from June 10, 2025, and the services will be provided in line with the company's payment schedule. This strategic partnership underscores Kairos Pharma's dedication to ensuring that its operations and financial health are communicated effectively to a wide range of audiences.
References
[1] https://www.benzinga.com/analyst-stock-ratings/analyst/591c741c290fa70001b157cb/jason-kolbert
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios